Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.54 |
| ▸ | SMO | Q99835 | 1/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD5 | P21918 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8438497 | 0.92 | MAOA (0.55) | MAOAMAOBSLC18A3SMOCXCR3 | |
| SCHEMBL28286738 | 0.89 | SLC18A3 (0.61) | MAOAMAOBSLC18A3SMOCXCR3 | |
| SCHEMBL10263767 | 0.85 | SLC18A3 (0.67) | MAOAMAOBSLC18A3SMOCXCR3 | |
| SCHEMBL27781945 | 0.84 | SLC18A3 (0.65) | MAOAMAOBSLC18A3CXCR3MCOLN2 | |
| SCHEMBL8259450 | 0.83 | HRH3 (0.50) | MAOAMAOBSLC18A3SMOCXCR3 | |
| SCHEMBL8436469 | 0.82 | MAOA (0.51) | MAOAMAOBSLC18A3DRD2DRD1 | |
| SCHEMBL30823779 | 0.81 | SLC18A3 (0.50) | MAOAMAOBSLC18A3SMOCXCR3 | |
| SCHEMBL22360347 | 0.81 | SLC18A3 (0.50) | MAOAMAOBSLC18A3SMOCXCR3 | |
| SCHEMBL2299038 | 0.81 | SLC18A3 (0.53) | MAOAMAOBSLC18A3SMOCXCR3 | |
| SCHEMBL9115585 | 0.81 | SLC18A3 (0.53) | MAOAMAOBSLC18A3SMOCXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2508526-A1 | Spiroalkene carboxamide derivatives and their use as chemokine receptor modulators | Ares Trading SA (CH) | 2012-10-10 | — | — | EP | disclosed |
| WO-2012130915-A1 | SPIROALKENE CARBOXAMIDE DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTOR MODULATORS | ARES TRADING S.A. (CH) | 2012-10-04 | — | — | WO | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | MAOA 830/4885MAOB 1236/4885SLC18A3 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.